NCT07123090 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT07123090
Title	A Phase 2 Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma (SPARCC)
Acronym	SPARCC
Recruitment	Not yet recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Stephanie Berg
Indications	renal cell carcinoma with MiT translocations renal cell carcinoma clear cell renal cell carcinoma sarcomatoid renal cell carcinoma
Therapies	Axitinib + Palbociclib + PF-06801591
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
Brigham and Women's Hospital		Boston	Massachusetts	02215	United States	Details
Dana-Farber Cancer Institute		Boston	Massachusetts	02215	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT07123090Clinical Trial Detail